NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
September 12, 2006 • Volume 3 / Number 35 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Treating Malignant Peripheral Nerve Sheath Tumors

Name of the Trial
Phase II Study of Neoadjuvant Chemotherapy Comprising Doxorubicin Hydrochloride and Ifosfamide Followed by Etoposide and Ifosfamide in Patients with Sporadic or Neurofibromatosis Type 1-Associated High-Grade Unresectable Stage III or IV Malignant Peripheral Nerve Sheath Tumors (NCI-06-C-0043). See the protocol summary at http://cancer.gov/clinicaltrials/NCI-06-C-0043.

Dr. Brigitte Widemann

Principal Investigator
Dr. Brigitte Widemann, NCI Center for Cancer Research

Why This Trial Is Important

Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that form in the outer layers of peripheral nerves (nerves outside the brain and spinal cord). About half of MPNSTs are found in individuals with a hereditary condition called neurofibromatosis type 1 (NF1). Surgery is the only curative treatment for MPNSTs. The prognosis for patients with unresectable tumors (tumors that cannot be surgically removed) is poor.

In this trial, patients with unresectable MPNSTs will be treated with neoadjuvant chemotherapy followed by surgery and/or radiation therapy and more chemotherapy. Neoadjuvant chemotherapy is given to reduce the size of the MPNSTs prior to the administration of definitive local therapy (surgery and/or radiation therapy). The choice of treatment following neoadjuvant chemotherapy will be based on tumor location and tumor response to the chemotherapy.

"We hope MPNSTs shrink in response to neoadjuvant chemotherapy with doxorubicin, ifosfamide, and etoposide, which are standard agents with proven activity in other pediatric and adult sarcomas," said Dr. Widemann.

"Furthermore, because outcomes for NF1-associated MPNSTs have been reported to be worse compared with sporadic tumors," Dr. Widemann said, "we will evaluate outcomes in the two groups treated with identical therapy to determine if patients with NF1-associated MPNSTs face a worse prognosis."

Who Can Join This Trial
Researchers will recruit 74 patients with newly diagnosed sporadic or NF1-associated high-grade stage III or IV MPNSTs. See the list of eligibility criteria at http://cancer.gov/clinicaltrials/NCI-06-C-0043.

Study Sites and Contact Information
Study sites in the United States are recruiting patients for this trial. See the list of study contacts at http://www.cancer.gov/clinicaltrials/NCI-06-C-0043, or call NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for more information. The toll-free call is confidential.


An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.